Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-12-2014 | Original Article – Clinical Oncology

Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients

Authors: Yue Qiu, Yuan Hu, Zuo-Yang Zhang, Lei Ye, Fei-Hong Xu, Marion E. Schneider, Xue-Ling Ma, Yi-Xin Du, Xian-Bo Zuo, Fu-Sheng Zhou, Gang Chen, Xu-Shi Xie, Yan Zhang, Hong-Zhen Xia, Ji-Feng Wu, Wei-Dong Du

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2014

Abstract

Purpose

(1) To investigate associations between single nucleotide polymorphisms (SNPs) in osteopontin (OPN) and its receptor—cluster of differentiation 44 (CD44) genes and gastric cancer susceptibility. (2) To explore the correlation of OPN and CD44 expression of gastric cancer.

Methods

We detected 26 SNPs of the genes in gastric cancer patients from the Chinese Han population by Sequenom technique and performed expression of OPN in combination with CD44 in 243 tissues samples of the cases by tissue microarray and immunohistochemistry (IHC).

Results

We found that the minor alleles of OPN rs4754C>T and OPN rs9138C>A remained strongly associated with decreased gastric cancer risk (P = 1.53 × 10⁻⁴, odds ratio (OR) 0.642, 95 % confidence interval (CI) 0.511–0.808 and P = 1.59 × 10⁻⁴, OR 0.642, 95 %CI 0.510–0.809). OPN variant rs1126772A>G and CD44 variant rs353639A>C significantly contributed to elevated risk of gastric cancer (P = 0.042, OR 1.279, 95 % CI 1.008–1.622 and P = 0.047, OR 1.334, 95 % CI 1.003–1.772). Haplotypes of OPN and CD44 variants significantly influenced risk of gastric cancer. Clinical data indicated that rs4754 and rs9138 of OPN were significantly associated with smoking (P = 0.029, OR 0.343, 95 % CI 0.127–0.926 and P = 0.029, OR 0.343, 95 %CI 0.127–0.926) and OPN rs1126772 revealed associations with tumor–node–metastasis (TNM) stage (P = 0.025, OR 1.765, 95 % CI 1.073–2.905) and tumor differentiation (P = 0.031, OR 1.722, 95 % CI 1.049–2.825). OPN expression was observed in 133 of the 243 cases (54.7 %) by IHC and was correlated with serosa invasion (P = 0.013), TNM stage (P = 0.003) and lymph node metastasis (P = 0.002). CD44 expression was found in 92 of the 243 cases (37.9 %) and was associated with tumor size (P = 0.005) and lymph node metastasis (P = 0.023), respectively. The OPN expression displayed a positive association with CD44 (P = 0.01, r _s = 0.164).

Conclusions

We found that the polymorphisms rs4754, rs9138 and rs1126772 of OPN gene and rs353639 of CD44 gene were significantly associated with gastric cancer. Our IHC data indicated that interaction of OPN and CD44 protein would promote progression and metastasis of gastric cancer.

Ando T, Ishikawa T, Kato H et al (2009) Synergistic effect of HLA class II loci and cytokine gene polymorphisms on the risk of gastric cancer in Japanese patients with Helicobacter pylori infection. Int J Cancer 125:2595–2602. doi:10.1002/ijc.24666 PubMedCrossRef

Ashkar S, Weber GF, Panoutsakopoulou V et al (2000) Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860–864PubMedCrossRef

Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64–71. doi:10.1038/nature07242 PubMedCentralPubMedCrossRef

Bendardaf R, Algars A, Elzagheid A et al (2006) Comparison of CD44 expression in primary tumours and metastases of colorectal cancer. Oncol Rep 16:741–746PubMed

Bhattacharya SD, Garrison J, Guo H, Mi Z, Markovic J, Kim VM, Kuo PC (2010) Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. Surgery 148:291–297. doi:10.1016/j.surg.2010.05.007 PubMedCentralPubMedCrossRef

Bourguignon LY, Zhu H, Shao L, Zhu D, Chen YW (1999) Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. Cell Motil Cytoskeleton 43:269–287. doi:10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5

Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3:285–298. doi:10.1038/nrg775 PubMedCrossRef

Castelli EC, Moreau P, Oya e Chiromatzo A et al (2009) In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum Immunol 70:1020–1025. doi:10.1016/j.humimm.2009.07.028 PubMedCrossRef

Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E (2009) Gastric cancer. Crit Rev Oncol Hematol 71:127–164. doi:10.1016/j.critrevonc.2009.01.004 PubMedCrossRef

Chen RX, Xia YH, Xue TC, Zhang H, Ye SL (2011) Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep 25:803–808. doi:10.3892/or.2010.1116 PubMed

Conne B, Stutz A, Vassalli JD (2000) The 3′ untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med 6:637–641. doi:10.1038/76211 PubMedCrossRef

Dai N, Bao Q, Lu A, Li J (2007) Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer. Oncology 72:89–96. doi:10.1159/000111108 PubMedCrossRef

D’Alfonso S, Barizzone N, Giordano M et al (2005) Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum 52:539–547. doi:10.1002/art.20808 PubMedCrossRef

Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107:1055–1061. doi:10.1172/JCI12980 PubMedCentralPubMedCrossRef

Doventas A, Bilici A, Demirell F, Ersoy G, Turna H, Doventas Y (2012) Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepatogastroenterology 59:2196–2201. doi:10.5754/hge10498 PubMed

Fisher LW, Jain A, Tayback M, Fedarko NS (2004) Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers. Clin Cancer Res 10:8501–8511. doi:10.1158/1078-0432.CCR-04-1072 PubMedCrossRef

Fong YC, Liu SC, Huang CY et al (2009) Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 64:263–270. doi:10.1016/j.lungcan.2008.09.003 PubMedCrossRef

Gerger A, Zhang W, Yang D et al (2011) Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res 17:6934–6943. doi:10.1158/1078-0432.CCR-11-1180 PubMedCrossRef

Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, Ravazzolo R (2004) Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 20:87–96. doi:10.1152/physiolgenomics.00138.2004 PubMedCrossRef

Hamajima N, Naito M, Kondo T, Goto Y (2006) Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 97:1129–1138. doi:10.1111/j.1349-7006.2006.00290.x PubMedCrossRef

Higashiyama M, Ito T, Tanaka E, Shimada Y (2007) Prognostic significance of osteopontin expression in human gastric carcinoma. Ann Surg Oncol 14:3419–3427. doi:10.1245/s10434-007-9564-8 PubMedCrossRef

Imano M, Satou T, Itoh T et al (2009) Immunohistochemical expression of osteopontin in gastric cancer. J Gastrointest Surg 13:1577–1582. doi:10.1007/s11605-009-0955-y PubMedCrossRef

Jansson M, Panoutsakopoulou V, Baker J, Klein L, Cantor H (2002) Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J Immunol 168:2096–2099PubMedCrossRef

Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK (2012) Expressions of osteopontin (OPN), alphanubeta3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin J Cancer Res 24:103–108. doi:10.1007/s11670-012-0103-1 PubMedCentralPubMedCrossRef

Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, Lunet N (2008) Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 19:689–701. doi:10.1007/s10552-008-9132-y PubMedCrossRef

Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36:D820–D824. doi:10.1093/nar/gkm904 PubMedCentralPubMedCrossRef

Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY (2007) Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44 V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 67:2089–2097. doi:10.1158/0008-5472.CAN-06-3625 PubMedCrossRef

Lee TY, Lin JT, Wu CC et al (2013) Osteopontin promoter polymorphisms are associated with susceptibility to gastric cancer. J Clin Gastroenterol 47:e55–e59. doi:10.1097/MCG.0b013e31827b9325 PubMedCrossRef

Likui W, Hong W, Shuwen Z (2010) Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer. J Gastrointest Surg 14:74–81. doi:10.1007/s11605-009-1035-z PubMedCrossRef

Lin YH, Yang-Yen HF (2001) The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 276:46024–46030. doi:10.1074/jbc.M105132200 PubMedCrossRef

Lin F, Li Y, Cao J et al (2011) Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells. Mol Biol Rep 38:5205–5210. doi:10.1007/s11033-010-0671-4 PubMedCrossRef

Maver A, Medica I, Salobir B, Tercelj M, Peterlin B (2009) Genetic variation in osteopontin gene is associated with susceptibility to sarcoidosis in Slovenian population. Dis Markers 27:295–302. doi:10.3233/DMA-2009-0675 PubMedCentralPubMedCrossRef

Neumann WL, Coss E, Rugge M, Genta RM (2013) Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 10:529–541. doi:10.1038/nrgastro.2013.101 PubMedCrossRef

Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4:33–45. doi:10.1038/nrm1004 PubMedCrossRef

Raheja LF, Genetos DC, Yellowley CE (2008) Hypoxic osteocytes recruit human MSCs through an OPN/CD44-mediated pathway. Biochem Biophys Res Commun 366:1061–1066. doi:10.1016/j.bbrc.2007.12.076 PubMedCrossRef

Rud AK, Boye K, Oijordsbakken M et al (2013) Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 13:540. doi:10.1186/1471-2407-13-540 PubMedCentralPubMedCrossRef

Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N (1998) Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83:1094–1101PubMedCrossRef

Samson PS, Escovidal LA, Yrastorza SG, Veneracion RG, Nerves MY (2002) Re-study of gastric cancer: analysis of outcome. World J Surg 26:428–433. doi:10.1007/s00268-001-0243-9 PubMedCrossRef

Tang H, Wang J, Bai F et al (2008) Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest 26:60–67. doi:10.1080/07357900701519279 PubMedCrossRef

Teramoto H, Castellone MD, Malek RL, Letwin N, Frank B, Gutkind JS, Lee NH (2005) Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12. Oncogene 24:489–501. doi:10.1038/sj.onc.1208209 PubMedCrossRef

Tolg C, Hofmann M, Herrlich P, Ponta H (1993) Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 21:1225–1229PubMedCentralPubMedCrossRef

Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333–345. doi:10.1016/j.cytogfr.2008.08.001 PubMedCrossRef

Wang Y, Yan W, Lu X et al (2011) Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avbeta3/PI3 K/AKT/eNOS/NO signaling pathway in glioma cells. Eur J Cell Biol 90:642–648. doi:10.1016/j.ejcb.2011.03.005 PubMedCrossRef

Weber GF, Ashkar S, Glimcher MJ, Cantor H (1996) Receptor–ligand interaction between CD44 and osteopontin (Eta-1). Science 271:509–512PubMedCrossRef

Weber GF, Ashkar S, Cantor H (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 109:1–9PubMed

Weber GF, Bronson RT, Ilagan J, Cantor H, Schmits R, Mak TW (2002) Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62:2281–2286PubMed

Winder T, Ning Y, Yang D et al (2011) Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer 129:1096–1104. doi:10.1002/ijc.25787 PubMedCentralPubMedCrossRef

Wu CY, Wu MS, Chiang EP et al (2007) Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782–789. doi:10.1136/gut.2006.109868 PubMedCentralPubMedCrossRef

Wu IC, Wu MT, Chou SH et al (2008) Osteopontin expression in squamous cell cancer of the esophagus. World J Surg 32:1989–1995. doi:10.1007/s00268-008-9609-6 PubMedCrossRef

Xia HZ, Du WD, Wu Q et al (2012) E-selectin rs5361 and FCGR2A rs1801274 variants were associated with increased risk of gastric cancer in a Chinese population. Mol Carcinog 51:597–607. doi:10.1002/mc.20828 PubMedCrossRef

Xiao M, Hu S, Zhang L, Huang J, Jiang H, Cai X (2013) Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population. Mutagenesis 28:577–582. doi:10.1093/mutage/get035 PubMedCrossRef

Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW, Fisher LW (1990) cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7:491–502PubMedCrossRef

Zhao F, Chen X, Meng T, Hao B, Zhang Z, Zhang G (2012) Genetic polymorphisms in the osteopontin promoter increases the risk of distance metastasis and death in Chinese patients with gastric cancer. BMC Cancer 12:477. doi:10.1186/1471-2407-12-477 PubMedCentralPubMedCrossRef

Zhou X, Wu CY (2012) Association of CD44 polymorphisms with genetic susceptibilities and clinico-pathologic characteristics in breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 43:807–811PubMed

Ziebarth JD, Bhattacharya A, Chen A, Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216–D221. doi:10.1093/nar/gkr1026 PubMedCentralPubMedCrossRef

Zohar R, Suzuki N, Suzuki K, Arora P, Glogauer M, McCulloch CA, Sodek J (2000) Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184:118–130. doi:10.1002/(SICI)1097-4652(200007)184:1<118:AID-JCP13>3.0.CO;2-Y PubMedCrossRef

Title: Genetic association of osteopontin (OPN) and its receptor CD44 genes with susceptibility to Chinese gastric cancer patients
Authors: Yue Qiu
Yuan Hu
Zuo-Yang Zhang
Lei Ye
Fei-Hong Xu
Marion E. Schneider
Xue-Ling Ma
Yi-Xin Du
Xian-Bo Zuo
Fu-Sheng Zhou
Gang Chen
Xu-Shi Xie
Yan Zhang
Hong-Zhen Xia
Ji-Feng Wu
Wei-Dong Du
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1761-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2014

Erratum to: Nationwide analysis on surgical procedures for patients with endometrial cancer in Germany: Results of the AGO pattern of care studies from the years 2013, 2009, and 2006

TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer

Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer

MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study

LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β-catenin

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage